Glad to share the outcomes of a recent manuscript, published on Graefe’s Archive for Clinical & Experimental Ophthalmology, assessing the performance of several clinically available riboflavin ophthalmic formulations for corneal cross-linking.
The C4V CHROMO4VIS theranostics device allowed the quantity of riboflavin permeating the human cornea to be precisely and non-invasively measured with epi-off and epi-on application protocols using the various ophthalmic solutions available in Europe and the United States.
The study demonstrated that RitSight significantly outperforms all available products for the treatment of pathological corneal conditions with corneal cross-linking procedures, with an average of four times the effectiveness of epi-on protocols.